Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 54c
Tweet
Share
E-mailGet Alerts SYRE Hot Sheet
Join SI Premium – FREE
Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($1.36), $0.54 worse than the analyst estimate of ($0.82).
For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Morgan Stanley upgrades Robinhood, sees 43% upside
- Designer Brands (DBI) PT Lowered to $6 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
